Petosemtamab

Merus announced that 79% of patients with newly diagnosed metastatic head and neck cancer survived at least one year when treated with petosemtamab in combination with Keytruda.

Shionogi & Co. plans to acquire Japan Tobacco's pharmaceutical subsidiaries Torii Pharmaceutical and Akros Pharma for ¥160 billion ($1.1 billion) to strengthen its global R&D capabilities.

Merus will present updated interim Phase 2 data on petosemtamab combined with pembrolizumab for first-line treatment of PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma at the 2025 ASCO Annual Meeting.

DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.

The global circulating DNA/RNA market is projected to grow from $5.32 billion in 2023 to $16.4 billion by 2032, advancing at a CAGR of 13.29% according to a new patent landscape report.